ReCET™
Novel Investigational Procedure for Type 2 Diabetes
Research shows that signaling from the small intestine (specifically the duodenum) is a key regulator of metabolic function, including blood sugar management in the body4,5. When signaling in the duodenum becomes abnormal the body lacks the ability to properly regulate blood sugar, contributing to the development and progression of Type 2 Diabetes (T2D).
The ReCET Procedure is investigational and is currently being evaluated in clinical studies. ReCET utilizes the principle of metabolic change through Intestinal Cellular Regeneration (ICR) to induce regrowth of healthy signaling cells in the duodenum with the intent to slow the progression of T2D, improve blood sugar control and reduce dependence on medication.
What is ReCET?
The ReCET Technology consists of a specialized catheter that delivers pulsed electric fields to the duodenum, initiating the body’s natural process of cellular regeneration. This is designed to promote stem cell directed regrowth of healthy cells with the goal of improving cellular signaling and the body’s ability to manage blood sugar levels.
The ReCET Procedure
The ReCET Procedure is investigational and is currently being evaluated in clinical studies. While the patient is asleep, a physician uses a small flexible camera (an endoscope) to introduce the ReCET Catheter through the mouth and past the stomach to the first part of the small intestine (duodenum). A small coil is deployed from the ReCET Catheter and a controlled, electric current is applied to the lining of the small intestine.
This delivery of energy is designed to trigger the body’s natural process to regenerate healthy cells that may help control blood sugar levels.
Help us change the way we treat Type 2 Diabetes
Clinical studies are underway to evaluate the ReCET Procedure. Learn more about our clinical studies as a clinical provider or patient.